Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06137157 | Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome | PHASE1 | RECRUITING | 12 | — | — | Jun 19, 2024 | Aug 1, 2026 | Feb 5, 2026 | 2 | United States |
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Internal controlled arm | EXPERIMENTAL | ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body. |
| Name | Type | Description |
|---|---|---|
| ATR12-351 | DRUG | Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis |
Inclusion Criteria: * Adults ≥18 years of age * Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene * Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome Exclusion Criteria: * Use of biologic therapies, antibiotics, antihista...